News

An artificial intelligence-powered communication app helps people with amyotrophic lateral sclerosis (ALS) and other conditions that affect speech keep communicating using a voice that sounds like their own. Called Voice Back, the augmentative and alternative communication (AAC) app can create a personalized voice from a short audio recording.

A progressive decline in lung function is unavoidable for many people with neuromuscular conditions such as amyotrophic lateral sclerosis (ALS), but there are steps that patients can take to ease breathing issues and improve quality of life. “We can’t really change the progression,” said James Rowley, MD, a pulmonologist at…

Low muscle mass in the arms and legs, as well as sarcopenia (low muscle mass and strength), were each linked to poorer survival in people with amyotrophic lateral sclerosis (ALS), a small prospective study in Spain found. “These findings suggest that muscle mass may provide prognostic information complementary to…

Otsuka Pharmaceutical’s experimental therapy ulefnersen improved a combined measure of function and survival compared with a placebo in people with amyotrophic lateral sclerosis (ALS) caused by mutations in the FUS gene. That’s according to top-line data from the first part of the ongoing, global Phase 3 FUSION clinical…

Molecular changes linked to inflammation and how brain cells process proteins and genetic material may occur before the onset of amyotrophic lateral sclerosis (ALS) symptoms, a study in a mouse model of SOD1-related ALS suggests. The findings also point to changes in the hypothalamus, a brain region involved in…

Researchers identified changes in 10 genes that may help diagnose or track amyotrophic lateral sclerosis (ALS), according to a computer analysis of thousands of genes. The study compared whole-blood samples from ALS patients and healthy individuals, uncovering nearly 1,000 genes with altered gene activity, along with related molecular pathways…

Acelot has dosed the first healthy volunteer in a Phase 1a clinical trial testing ACE-2223, its investigational oral treatment candidate designed to target aggregated TDP-43 in people with amyotrophic lateral sclerosis (ALS). In the vast majority of people with ALS, the TDP-43 protein moves to the wrong place in…

Geneuro has received a European patent for GNK-301, its experimental therapy designed to target a viral protein thought to contribute to amyotrophic lateral sclerosis (ALS), and plans to begin Phase 1 clinical trials in the second half of 2027. The antibody-based therapy was developed through a partnership between…

Paradromics’ investigational Connexus brain-computer interface (BCI) enabled a woman with a progressive motor neuron disease to generate her own words in real time, answer open-ended questions, and communicate with her family using synthesized speech. The woman, who had a severe impairment of her ability to speak, was the first…

Mindy Henderson has spent much of her life challenging the limits others have placed on her. When she was diagnosed with spinal muscular atrophy (SMA) — a genetic condition that causes muscles to weaken over time — as an infant, doctors told her parents that she might not live long…